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Abstract 
 
Background: Although chronic oral anticoagulation therapy reduces mortality and morbidity 
from thromboembolic diseases, the risk of bleeding and mortality may increase when patients on 
anticoagulation presents with acute ST elevation myocardial infarction (STEMI) where 
aggressive antiplatelet and further anticoagulation therapies are warranted. 
 
Objective: To study the characteristics of patients who are on oral anticoagulation therapy 
(OAC) at the time of presentation with acute STEMI. 
 
Design: Retrospective, cross-sectional study. 
 
Setting: All patients who presented to Christiana Care Health System, Newark, DE with acute 
ST elevation myocardial infarction with intent of primary percutaneous angioplasty between 
January 2009 and December 2010. 
 
Outcome Measures: Composite end-point of major bleeding, in-hospital death, cardiogenic 
shock, and cardiac arrest. Subgroup analysis of major bleeding and in-hospital mortality. 
 
Results: A total of 637 patients were enrolled into the study, the average age of the study 
population was 61 years, 71% male and 84% Caucasian patients. Of 637 patients, 20 (3.1%) 
were on OAC at the time of presentation. Both OAC and non-OAC groups differed in baseline 
characteristics including hypertension, diabetes mellitus, dyslipidemia, peripheral vascular 
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disease, previous coronary artery disease, and pre procedural laboratory data including 
hemoglobin and INR (all p < 0.05). The groups also differed in the treatment procedures. 
Patients who were on OAC were more likely to receive bare metal stents and clopidogrel and 
less likely to be treated with newer antiplatelet agents (prasugrel and ticagrelor) and drug eluting 
stents (all p <0.05). However, the composite endpoint (death, bleeding, and transfusion) was 
similar in both groups. On multivariable logistic regression analysis, use of anticoagulation and 
baseline INR were not significant independent predictors of study endpoints. Pre procedural 
hemoglobin (OR: 0.88, 95%CI: 0.77-0.98, p=0.012) and requirement of IABP (OR: 4.13, 95% 
CI: 2.25-7.59, p<0.001) were independent risk factors for study end points. 
 
Limitations: Overall sample size for patients who were on anticoagulation was limited due to 
the low (3%) observed prevalence in the study population, however it is similar to other 
published studies. The inclusion bias resulting from prehospitalization deaths may influence the 
results.  
 
Conclusions: The contemporary management of acute ST elevation myocardial infarction does 
not seem to raise the risk of bleeding, in-hospital death, or blood transfusion in patients who are 
on full anticoagulation.  
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Introduction 
 
Chronic Oral Anticoagulation  
Chronic anticoagulation is widely used to reduce the risk of thromboembolism. The most 
common indications for use of long-term anticoagulation are atrial fibrillation, venous 
thromboembolism (e.g.: deep venous thrombosis or pulmonary embolism), and patients with 
mechanical heart valves. It is estimated that 4 million patients in the US and nearly 7 million 
patients worldwide are on long-term therapy with oral anticoagulants, primarily warfarin or other 
coumarin derivatives, for prevention and treatment of venous and arterial thromboembolism [1]. 
Selected indications and target doses as recommended by the American College of Chest 
Physicians Evidence-Based Clinical Practice Guidelines 2012 are shown in Table I. Nearly 31 
million warfarin prescriptions were filled in 2004 in the USA [2]. 
 
Drugs are commonly used to achieve therapeutic anticoagulation by interfering with clotting 
cascade (Figure 1).  Activation of the clotting system ultimately generates fibrin which stabilizes 
and forms the backbone of a blood clot. There are 3 main classes of drugs suitable for long term 
oral anticoagulation. Warfarin, the most commonly used of long-term oral anticoagulant, is a 
vitamin K Antagonist. Warfarin has been used in clinical practice for more than 50 years. 
Vitamin K antagonists function by inhibiting the enzyme vitamin K epoxide reductase, which 
uses vitamin K for post-translational modification of several coagulation proteins (factor VII, 
factor IX, factor X and prothrombin). Dabigatran, a competitive and reversible direct thrombin 
inhibitor is a second type of the drug that was approved by FDA in October 2010 for use in atrial 
fibrillation. A third class of medications that were approved for long term oral anticoagulation 
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are direct Factor Xa inhibitors such as Apixaban and Rivaroxaban. Apixaban was approved by 
FDA in 2012 reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial 
fibrillation. Rivaroxaban was approved for prophylaxis of DVT in 2011 followed by approval for 
stroke prevention in patients with non-valvular atrial fibrillation. In 2012 rivaroxaban was also 
approved for the treatment DVT and PE. Parenteral heparin and low molecular weight heparin 
are also occasionally used for long-term anticoagulation and to bridge anticoagulation 
interruption when surgical procedures are required. 
 
Table I: Selected Anticoagulation Recommendations from the 9th Edition of the American 
College of Chest Physicians Evidence-Based Clinical Practice Guidelines.[3]: 
Indication INR Range Duration (level of evidence) 
Antiphospholipid Syndrome 2.0-3.0 indefinite (2B) 
DVT and PE 
Transient/reversible risk factor 2.0-3.0 3 months (1B) 
Unprovoked 2.0-3.0 at least 3 months (1B) then 
reevaluate 
Second episode of unprovoked 2.0-3.0 extended (1B) 
Non-Valvular Atrial Fibrillation/Atrial Flutter 
CHADS2 Score = 0 (low CVA risk) N/A no therapy (2B) or aspirin 75-
325mg (2B) 
CHADS2 Score = 1 (intermediate CVA risk) N/A  Long-term with dabigatran (2B) 
CHADS2 Score ≥ 2 (high CVA risk) 2.0-3.0 Long-term, or long-term 
dabigatran (2B) 
With mitral stenosis 2.0-3.0 long-term (1B) 
With stable CAD 2.0-3.0 long-term (2C) 
Prior to/following cardioversion to sinus 
rhythm 
2.0-3.0 3 weeks/4weeks (1B) 
Mechanical Heart Valve 
Aortic 2.0-3.0 long-term (1B) 
Mitral 2.5-3.5 long-term (2C) 
Bioprosthetic heart valve 
Aortic N/A aspirin 50-100mg (2C) 
Mitral 2.0-3.0 3 months then switch to ASA (2C) 
   
Cardioembolic Ischemic Stroke N/A dabigatran (2B) 
CAD: coronary artery disease; CHADS2 Score: a clinical prediction scoring rule for estimating 
the risk of stroke in patients with non-rheumatic atrial fibrillation which ranges between 0 and 6; 
DVT: Deep vein thrombosis; INR: international normalized ratio; PE: pulmonary embolism. 
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Figure 1: Targets of anticoagulant drugs. When tissue factor is exposed to the blood it binds 
to the plasma protein factor VIIa (the extrinsic pathway, red). This complex triggers activation of 
the coagulation cascade through the proteolytic cleavage of both factor X and factor IX and 
ultimately generates fibrin which on polymerization stabilizes platelet thrombi. The coagulation 
cascade is amplified by the tenase complex, which consists of factor VIIIa and factor IXa 
(components of the intrinsic pathway, blue). Factor XIa and factor XIIa might also help to 
activate the coagulation cascade under pathological conditions. Triggers of thrombosis are shown 
in bold face. Anticoagulant drugs that are in current use and in development (grey) are listed 
with their targets (red blocking arrows). Reprinted by permission from Macmillan Publishers 
Ltd: Nature [4], copyright 2008. 
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Effectiveness of long-term anticoagulation in reducing thromboembolic risk has been well 
established. In a meta-analysis involving 28,000 patients who have atrial fibrillation, adjusted-
dose warfarin was shown to reduce stroke by approximately 60% and death by approximately 
25% compared with no antithrombotic treatment [5]. In RE-LY trial, which is a non-inferiority 
double blind study, patients treated with dabigatran showed rates of stroke and systemic 
embolism that were similar to those patients who were treated with warfarin (relative risk with 
dabigatran, 0.91; 95% CI, 0.74-1.11; P<0.001 for non-inferiority) [6]. Similarly in ARISTOTLE 
study, apixaban was shown to be superior to warfarin in reducing stroke in patients with atrial 
fibrillation (hazard ratio in the apixaban group, 0.79; 95% CI: 0.66 - 0.95; P<0.001 for non-
inferiority and P=0.01 for superiority) [7]. In ROCKET-AF trial, rivaroxaban was also shown 
non-inferior to warfarin (hazard ratio, 0.88; 95% CI, 0.74 to 1.03; P<0.001 for non-inferiority; 
P=0.12 for superiority) [8]. Overall, these studies showed that the average annual risk of stroke 
in atrial fibrillation is 1.6-1.7 % when treated by warfarin, 1.1% when treated by dabigatran and 
1.2 % when treated by apixaban [6, 7].  
 
Atrial fibrillation poses a significant risk for development of stroke and warrants lifelong 
anticoagulation therapy in a majority of patients. Various risk prediction models have been 
developed to predict the risk of future stroke in patients with non-valvular atrial fibrillation. The 
CHADS2 score, is a commonly used tool in the clinical practice, estimates the risk of stroke, 
which is defined as focal neurologic signs or symptoms that persist for more than 24 hours and 
that cannot be explained by hemorrhage, trauma, or other factors, or peripheral embolization, 
excluding transient ischemic attacks [9] . CHADS2 is an acronym for Congestive heart failure, 
Hypertension, Age>75, Diabetes mellitus, and prior Stroke and the score is calculated by giving 
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1 point to each condition except stroke which is given 2 points. Therefore CHADS2 score ranges 
from 0 to 6. A score of 0 is considered low risk, a score of 1 or 2 is considered intermediate risk, 
and a score ≥3 is considered high risk for stroke. The predicted annual risk of stroke and effect of 
warfarin in patients with atrial fibrillation is shown in Table II. 
 
Table II: CHADS2 score, thromboembolic risk, and effect of warfarin anticoagulation 
CHADS2 score 
Events per 100 person-years* 
NNT 
Warfarin No warfarin 
0 0.25 0.49 417 
1 0.72 1.52 125 
2 1.27 2.50 81 
3 2.20 5.27 33 
4 2.35 6.02 27 
5 or 6 4.60 6.88 44 
All differences between warfarin and no warfarin groups are statistically significant except for a 
trend with a CHADS2 score of 0. NNT: number needed to treat to prevent one stroke per year 
with warfarin. Data from [9, 10] 
 
Complications of OCA Therapy 
The major risk of anticoagulation therapy is bleeding. The FDA’s Adverse Event Reporting 
System indicated that warfarin is among the top 10 drugs with the largest number of serious 
adverse event reports submitted during the 1990 and 2000 decades. From US death certificates, 
anticoagulants ranked first in 2003 and 2004 in the number of total mentions of deaths for drugs 
causing “adverse effects in therapeutic use” [2]. Compared to placebo use, warfarin use is 
associated with a relative risk of 4.8 (95% CI, 2.1-10.8) for fatal bleeding and relative risk of 6.6 
(95% CI, 4.0-10.8) for major bleeding. The mean annual frequency of fatal bleeding events was 
0.6% (95% CI, 0.4%-0.7%) and major bleeding events were 3.0% (95% CI, 2.6%-3.4%) [2]. 
Similarly, a population based study has shown that in patients with atrial fibrillation who are on 
warfarin, the rate of hemorrhage was 3.8% (95% CI 3.8%–3.9%) per person-year [11]. Newer 
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oral anticoagulation agents had similar bleeding rates that were comparable to warfarin in the 
initial studies [6-8]. However a meta-analysis of the risk of gastrointestinal bleeding with newer 
anticoagulant agents showed increased risk with an overall odds ratio of 1.45 (95% CI: 1.07-
1.97) and on subgroup analyses the odds ratio for patients with atrial fibrillation was 1.21 (95% 
CI, 0.91-1.61). 
 
 
Coronary Artery Disease  
Cardiovascular disease is the leading cause of death and a major cause of disability worldwide. 
In the USA, cardiovascular disease remains the most common cause of death. There has been  
significant improvement in cardiovascular mortality with cardiovascular related age-adjusted 
mortality declining from 588.8 deaths per 100,000 in 1950 to 179.1 deaths per 100,000 people in 
2010 [12]. The decline in death rate was attributed to various scientific modalities and primary 
management of coronary artery disease (Fig 2). However, cardiovascular disease and coronary 
artery disease remain the leading causes of morbidity and mortality. 
 
Clinically coronary artery disease (CAD) represents a spectrum of symptoms and syndromes 
ranging from asymptomatic clinical finding, chronic stable angina, acute coronary syndromes, 
and sudden death. Acute coronary syndrome (ACS) is a unifying term representing a common 
end result, acute myocardial ischemia. ACS itself represents another spectrum of clinical 
syndromes of acute MI and STEMI represents the most lethal form of ACS, one in which a 
completely occlusive thrombus results in total cessation of coronary blood flow in the territory of 
the occluded artery and resultant ST-segment elevation on the ECG. 
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Figure 2: Decline in Deaths from Cardiovascular Disease in Relation to Scientific Advances. The 
timeline shows the steady decline in cardiovascular deaths over the late 20th and early 21st 
centuries, along with major advances in cardiovascular science and medicine. ALLHAT denotes 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, CASS Coronary 
Artery Surgery Study, GISSI Italian Group for the Study of Streptokinase in Myocardial 
Infarction, HMG-CoA 1-hydroxy-3-methylglutaryl coenzyme A, ISIS-2 Second International 
Study of Infarct Survival, MI myocardial infarction, NCEP National Cholesterol Education 
Program, NHBPEP National High Blood Pressure Education Program, PCI percutaneous 
coronary intervention, SAVE Survival and Ventricular Enlargement, and TIMI 1 Thrombolysis 
in Myocardial Infarction 1. Reproduced with permission from [13], Copyright Massachusetts 
Medical Society. 
 
 
ST Elevation Myocardial Infarction  
Although the incidence of CAD was reduced over last few decades, most observational studies 
have not documented a reduction in the incidence of MI in a variety of time periods [14-17], 
such as between 1987 and 2006 [18]. Approximately 865,000 new acute myocardial infarctions 
(AMIs) occur in the United States every year [ref] and nearly 500,000 of them are ST-segment 
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elevation MI (STEMI) [19]. Of all presentations of ACS, STEMI is associated with the highest 
mortality.  
 
Further, the accurate and immediate diagnosis of STEMI is of paramount importance for two 
reasons. First, the diagnosis mandates immediate consideration for reperfusion therapy, either by 
thrombolytic agents or by mechanical revascularization, most probably PCI. Mortality has been 
significantly decreased by reperfusion within 12 hours of onset of symptoms in patients with 
STEMI. However, both pharmacologic and mechanical means of reperfusion have potentially 
fatal side effects or complications and should not be employed unless the diagnosis is relatively 
certain. To prevent unnecessary dangers, guidelines were developed. 
 
Treatment, Complications and Prognosis of STEMI 
During the last 3 decades, reperfusion therapies have improved progressively by a number of key 
steps: (1) the development of tissue plasminogen activators, more potent in lysing thrombi than 
streptokinase; (2) the addition of aspirin and then more potent antiplatelet agents to the 
fibrinolytic; (3) the use of percutaneous coronary angioplasty following STEMI in place of 
fibrinolytics; (4) the addition of stents – first bare metal then drug-eluting stents – following 
intracoronary balloon inflation; and most recently (5) by aspiration thrombectomy prior to 
coronary stenting. As a consequence of these measures, each of which improved clinical 
outcomes, in-hospital mortality from STEMI in the general population again declined by half, 
from 15% to about 7.5% and it is now as low as 3.5% in patients who are enrolled in clinical 
trials [20] and about 4.8% in large population based registry studies [21]. However, the therapies 
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are also associated with complications. Non-fatal complications due to acute MI are shown in 
Table III.  
 
Mortality from complications of acute MI is variable. Mechanical complications are associated 
with significant mortality while inflammatory complications are usually benign. Patients who 
developed ventricular septal defect after MI had a 30-day mortality rate of 94% when medically 
managed and 47% when surgically managed [22]. Papillary muscle rupture resulting in acute 
mitral regurgitation was found in 7% of patients in cardiogenic shock and contributes to 5% of 
the mortality after acute MI [23]. However, change in reperfusion strategy from thrombolysis to 
angioplasty resulted in an 82% decrease in the rate of acute MR, as compared with thrombolytic 
therapy (0.31% vs 1.73%) [24]. 
 
Table III: Non-fatal complications of Acute Myocardial Infarction. 
Complication 
Type 
Manifestations Incidence 
Ischemic Angina, reinfarction, infarct extension 5% - 30% 
Mechanical Heart failure, cardiogenic shock, mitral valve 
dysfunction, aneurysms, cardiac rupture 
VSD: 0.2% 
MR: 13% to 45% 
CHF: 7-8% 
Arrhythmic Atrial or ventricular arrhythmias, sinus or 
atrioventricular node dysfunction 
VFib: 2-4% 
Embolic Central nervous system or peripheral embolization Approx. 2% 
Inflammatory Pericarditis Approx. 10% 
 CHF: Congestive heart failure, MR: Mitral regurgitation, VFib: Ventricular fibrillation, VSD: 
Ventricular septal defect. 
 
Complications of Primary PCI 
Complications of primary PCI are similar to those seen during cardiac catheterization, those that 
occur as a consequence of the specific equipment (e.g., wires) required for the intervention, those 
related to aggressive antiplatelet and anticoagulant therapies, or those related to the intervention 
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itself. Most commonly reported complications from primary PCI are mortality, and bleeding. 
Various risk predictor tools were developed in ACS to identify the patients who are at risk of 
developing these complications [25-27]. Other reported complications include vascular access 
site complications, acute kidney injury from iodinated contrast media, peripheral vascular 
disease, myocardial ischemia, coronary artery injury from the procedure itself. 
 
Outcomes of ACS (Other than STEMI) while on OAC  
Results from randomized studies have shown that the annual risk of acute MI in patients treated 
with warfarin is about 0.64% [28]. In 2004, it was estimated that there were 4 million patients on 
warfarin therapy and the use of warfarin is increasing [2]. A large national level registry based 
study using National Cardiovascular Data Registry evaluated the association between home 
warfarin use and in-hospital mortality and bleeding in patients undergoing PCI [29]. The authors 
studied 11,173 patients and nearly 3.6% of patients were on home warfarin therapy. In the study, 
patients taking warfarin were less likely to receive aspirin, theinopyridines, and glycoprotein 
IIb/IIIa inhibitors during PCI. Unadjusted bleeding rates (elective PCI = 3.2% vs 1.9%; urgent 
PCI = 8.2% vs 4.8%) and in-hospital mortality (elective PCI = 1.4% vs. 0.6%; urgent PCI = 
8.6% vs. 4.5%) were higher among patients taking warfarin. After adjustment for clinical 
characteristics, the risk of in-hospital mortality was similar with and without previous warfarin 
use. However, the adjusted risk of bleeding was significantly higher in patients receiving 
warfarin, for both elective (odds ratio = 1.26, 95% CI 1.09 - 1.46) and urgent PCI (odds ratio = 
1.42, 95% CI 1.14 - 1.76).  However, the study also included patients who had rescue and 
facilitated PCI where patients received thrombolytic therapy in addition to PCI. The inclusion of 
patients who received thrombolytics may have skewed some of the results as thrombolytic 
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therapy is a well-established risk factor for major bleeding compared to primary PCI patients 
alone. 
 
Another study using NCDR ACTION Registry®-GWTG™ data studied the early antithrombotic 
treatment and invasive therapy, and risk of in-hospital major bleeding outcomes of non-STEMI 
patients by admission international normalized ratio (INR) levels defined as subtherapeutic (INR 
<2), therapeutic (INR 2-3), and supratherapeutic (INR >3) [30]. Risk of major bleeding was 
higher among patients with therapeutic (15%, adjusted odds ratio [OR] 1.25, 95% confidence 
interval [CI] 1.03-1.50) and supratherapeutic anticoagulation (22%, OR 1.60 [1.30-1.97]) 
compared with the subtherapeutic group (12%). Among patients with admission INR ≥2, 45% 
were treated with early (within 24 hours) heparin, 35% with early clopidogrel, 14% with early 
glycoprotein IIb/IIIa inhibitor (GPI), and 36% with early invasive strategy. Early antithrombotic 
treatment was associated with increased bleeding risk (OR 1.40 (5% CI: 1.14-1.72) for heparin; 
1.50 (95% CI: 1.22-1.84) for clopidogrel; 1.82 (95% CI: 1.43-2.32) for GP IIb/IIIa inhibitors); 
however, an early invasive strategy was not (OR 1.09 (95% CI: 0.86-1.37). No significant 
interactions were observed between INR level and use of each early treatment in its association 
with bleeding but early antithrombotic treatment was associated with increased bleeding risk 
regardless of admission INR level [30]. 
 
Prior Literature and Studies on Outcomes of OAC in STEMI 
Extensive literature search yielded only limited data in the outcomes of patients who were on 
anticoagulation at the time of presentation with acute STEMI. Three studied were identified 
which studied the outcomes of OAC in acute MI and summarized in table IV 
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The first study reported by Oudot et al in 2006 studied 2112 French patients with acute 
myocardial infarction [31]. The study period was year 2001 which showed nearly 4% of patients 
were on long term anticoagulation and only 9% of the anticoagulation group received 
thrombolytic therapy compared to 42% in no anticoagulation group and only 74% of patients had 
coronary angiogram compared to 93% in no anticoagulation group. The study showed that 
anticoagulation is not associated with major in-hospital bleed, and long term data was not 
studied. 
 
In the second study published by Vecchio et al compared the in-hospital outcomes of patients on 
anticoagulation who presented with STEMI to patients with non-STEMI acute coronary 
syndromes (non- ST elevation myocardial infarction and unstable angina) from year 2007 [32]. 
The in-hospital occurrence of death (3.7% vs. 1.1%; OR 3.3; 95% CI: 0.2-56.0), stent thrombosis 
(3.7% vs. 1.1%; OR 3.3; 95% CI 0.2-56.0) and major bleeding (7.4% vs. 2.2%; OR 3.4; 95% CI 
0.4-25.9) were shown to be higher in STEMI patients who underwent primary PCI compared to 
non STEMI related ACS patients who underwent non-emergent PCI. Most of the patients 
received unfractionated heparin during the procedure [32]. 
 
A large national level registry based study from NCDR ACTION registry showed that warfarin 
use is predictive of major in-hospital bleeding in patients with STEMI and NSTEMI with an 
adjusted odds ratio of 1.18 (95% CI: 1.07–1.30) [33]. The data also showed that nearly 5% of the 
patients in USA are on anticoagulation at the time of presentation with STEMI or NSTEMI. 
However, the study did not include mortality data or long-term follow-up and also excluded 
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patients who died within 24 hours of presentation. Further, there was no data on the type of 
antiplatelet and antithrombotic agents used in the management (Table IV). 
 
 
Rationale for the study 
The direct evidence from existing literature on the outcomes of STEMI patients who were on 
OAC compared to those who were not on OAC is limited. Moreover, the existing data does not 
reflect contemporary guidelines in management of STEMI patients undergoing primary PCI [19]. 
Recent guidelines from ACC/AHA suggests the door-to-balloon time should be less than 90 min 
for primary PCI which may preclude some patients from receiving anticoagulation reversal 
agents such as fresh frozen plasma or vitamin K. When anticoagulation reversal agents were not 
used, further antiplatelet and antithrombotic agents may raise risk of bleeding and or death. 
When attempts are made to reverse anticoagulation, it may prolong door-to-balloon time and 
may also result in unfavorable outcomes. It was also shown that risk of bleeding increases 
significantly when OAC therapy is combined with antiplatelet therapy [34-36]. Antiplatelet 
therapy forms the cornerstone of management of ACS patients including STEMI. Thus there is 
clear concern for the safety and outcomes in the particular groups of patients who are on full 
anticoagulation. Further, no guidelines exist in the management of this subgroup of patients. 
Given the knowledge gap in the outcomes of the specific group of patients in the contemporary 
era, we proposed to study the outcomes of the patients in terms of major bleeding and death 
when presented with STEMI while on long-term anticoagulation. 
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Study Objectives 
The primary aims 
1.  To determine the prevalence of OAC use in patients OAC use in patients with acute 
STEMI undergoing primary PCI  
2. To describe the process of care of and short-term outcomes of primary PCI in patients 
with acute STEMI undergoing primary PCI 
3. To compare overall outcomes in primary PCI for acute STEMI patients who are on OAC 
to those who were not on OAC.  
Secondary aims: 
1.  To study whether OAC is an independent predictor of the combined end point of in-
hospital death, and major bleeding among patients who presented with acute STEMI.  
2. To study whether OAC use is an independent predictor of individual outcomes of major 
bleeding, and in-hospital mortality in a subgroup analysis. 
 
 
Methods 
Location and subjects 
The study was designed a retrospective cross-sectional study involving all patients who had 
acute ST elevation myocardial infarction and were admitted to Christiana Care Health System, 
Newark, DE between January 2009 and December 2010 for primary PCI. Locally, door-to-
balloon time of less than 90 min in majority of patients with acute STEMI was achieved and 
maintained since 2009. Similarly, first alternative to warfarin was approved for chronic 
anticoagulation in October 2010 by FDA and has gained more popularity since 2011. Therefore, 
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to avoid potential cohort effect, the above time period was chosen. Christiana Care Health 
System is a large academic community medical center with 1000 beds with an average 53,000 
admissions and 165,000 emergency room visits per year. On average, Christiana Care’s cardiac 
catheterization lab performs more than 5,000 diagnostic and 2,000 interventional procedures per 
year.  
 
At Christiana Care Health System, when a patient suspected of acute MI is encountered, 
typically a “heart alert” is called in where all personnel and resources required for primary PCI 
(interventional cardiologist, cardiac catheterization lab and technologist and nursing staff) are 
immediately alerted. After careful discussion and evaluation of patient, decision to perform 
emergency cardiac catheterization is usually made within few minutes and a “heart code” will 
then be called where all the resources are immediately activated and patient is taken to the 
catheterization lab within few minutes. The details of all heart alerts and heart codes are 
maintained in an electronic database. Further, cardiac catheterization lab maintains an electronic 
database where indications, procedural details, complications and outcomes of all patients who 
had any PCI done. After patient is discharged home, the data is manually verified and updated by 
a registered nurse and usually a subset of this data is submitted to national level registries as 
required on quarterly basis.  
 
Inclusion and exclusion criteria 
Inclusion criteria: 
1. All patients who were aged more than 18 years and were admitted to Christiana Care 
Health System with the diagnosis of acute ST elevation myocardial infarction within 24 
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hours after symptom onset and went to cardiac catheterization lab with intent of primary 
PCI  
Exclusion criteria: 
1. Patients who had thrombolytics prior cardiac catheterization (ex: salvage or facilitated 
PCI)  
2. Patients who developed STEMI during hospital stay where originally admitted for non-
myocardial infarction related problems 
3. Acute in-stent thrombosis  
4. Acute STEMI after coronary artery bypass surgery (CABG) 
 
Definitions 
The definitions used in the study were the standard definitions as describe by ACC NCDR 
registry. The full lengths of the definitions are given in appendix 1. Briefly, STEMI is defined as 
acute coronary syndrome of less than 24 hour onset with documented ST elevation on 12-lead 
surface ECG as per standard definition. Anticoagulation use is defined as the use of full 
therapeutic dose of any accepted medications (oral warfarin, or oral dabigatran) for at least 4 
weeks prior index admission. The laboratory measurement of INR is only included if measured 
before the beginning of the procedure. Post procedural and INR drawn after administering 
medications such as heparin were also excluded in the analysis as the mentioned treatments may 
falsely elevate INR values. In such a situation, INR value is treated as missing.  
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Data Collection 
All eligible patients were identified by electronic query of the cardiac catheterization laboratory 
database and heart code database. Patients who had the diagnosis of STEMI were identified. The 
database was also queried for demographic, past medical history and comorbidity, procedural, 
pre-procedural laboratory, complication and outcomes data. The database lacks information of 
the home medications and some of the comorbid conditions. Therefore, all medical records of the 
index admission were reviewed manually by the investigator. The eligibility criteria were 
reconfirmed by confirming the 12 lead ECG recordings and cardiac catheterization reports as 
well as physician notes. The data on variables that could not be electronically queried were 
manually entered into a separate electronic database. The demographic data was compared to 
United States Social Security Administration's Death Master File updated till March 31, 2013. 
 
Study Approval and Reporting. 
The study proposal was reviewed and approved by the Institutional Review Board at Christiana 
Care Health System, Newark DE (Reference: CCC#33096). A copy of approval is included in 
the Appendix. The results from the study were written using STROBE guidelines for cross-
sectional studies and check list is included in the appendix. 
 
Statistical Analysis 
The statistical analysis was performed in the overall STEMI patients, and by grouping subjects in 
to 2 groups. Group 1 includes those patients who are not on long-term anticoagulation at the time 
of presentation and group 2 includes those patients who are on full anticoagulation. Initially, all 
continuous variables were analyzed and confirmed normal distribution. For primary outcome 
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analysis, the study participants were divided into two groups based on their anticoagulation use. 
Baseline demographic, medical history, home medications, procedural details and outcomes 
were analyzed using univariate analyses. All continuous variables were expressed as mean ± 
standard deviation and Student’s t-test was used to compare patients who were on OAC to those 
who were not on OAC at the time of presentation. Similarly, categorical variables were 
expressed in percentages and chi-square test or Fisher Exact test were used to compare between 
the groups.  
 
For secondary outcome analysis, the outcome variables composite end point, mortality and 
bleeding were analyzed in separate analyses using multivariable logistic regression modeling 
using stepwise approach. Variables associated with a P-value < 0.2 in the univariate analysis 
were selected for multivariable analysis and anticoagulation status was retained in the modeling 
process. The number of variables was limited to 1 per 10 subjects with outcome measure. To 
avoid confounding, home medications other than warfarin were not used in the modeling as the 
medication use correlated with the medical history. The final model was tested for goodness-of-
fit using Hosmer-Lemeshow test. Results were expressed as odds ratio (OR) with 95% 
confidence interval (CI). A two-sided P-value <.05 was considered statistically significant for all 
analyses. All software analyses were conducted using SAS Software version 9.3 (Cary, NC). 
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Results: 
A total of 675 patients cardiac catheterizations were performed on patients with the diagnosis of 
acute STEMI during the study period. A total of 38 patients were excluded (21 patients had MI 
while admitted as an in-patient for other medical problems, and 17 patients had acute in-stent 
thrombosis) (Figure 3). Of the 637 patients analyzed, 20 patients (3.1%) were on full long-term 
anticoagulation at the time of admission and grouped into group 2 while the remaining 617 
(96.1%) were included in group 1. Baseline characteristics, past medical history and medications 
at the time of admission are shown in table 1. Procedural details are shown in table 2 and 
outcome details are shown in table 3. 
 
Descriptive Statistics 
Patients who were not on anticoagulation were significantly younger than those who were on 
anticoagulation (61±13 vs 67±12, p= 0.039). Other demographic features including gender (Male 
72% vs 55%, p 0.11), BMI (29±6 vs 31±9, p=0.51) and race (Caucasian 83% vs 80%, p=0.88). 
The prevalence of comorbid conditions was significantly higher in patients who were on 
anticoagulation compared to those who were not including hypertension, diabetes, dyslipidemia, 
family history of premature coronary disease, peripheral vascular disease, previous history of 
MI, prior PCI, congestive heart failure, atrial fibrillation (All p vales < 0.05, see Table 1). Similar 
to the comorbid conditions, the number of daily medications used by patients who were on 
anticoagulation are also higher compared to those people who were not on anticoagulation.  
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Figure 3: Summary flow chart of study cohort. A total of 675 patients were identified with acute 
STEMI during the study period. A total of 38 patients were excluded (21 patients developed 
STEMI during hospital stay while admitted for non-myocardial infarction related reasons and 17 
patients developed acute in-stent thrombosis after elective PCI procedure). Group 2 includes 20 
patients were on OAC therapy and remaining patients (617) were included in group 1. Summary 
of outcomes were also included.  
 
 
There was no difference between the 2 groups in LVEF and initial troponin levels. Patients on 
anticoagulation had significantly lower hemoglobin levels (12.5 ± 2.3 vs. 14.3 ± 2.1, p =0.001) 
and higher INR (2.1 ± 1 vs. 1.2 ± 0.3, p<0.001) (Table 2). During procedure, there was no 
significant difference on the type of arterial access, contrast volume given, fluoroscopy times 
between both groups.  Overall, the majority of patients received aspirin (84%) and bivalirudin 
Outcomes 
Combined Endpoint (89) 
In Hospital Mortality (38) 
Bleeding (27) 
Combined Endpoint (3) 
In Hospital Mortality (2) 
Bleeding (0) 
Groups 
Not on OAC (N=617) On OAC (N=20) 
Exclusions (38) 
Acute In-Stent Thrombosis (17) 
Acute MI while Admitted for Other Reasons (21) 
Total STEMI Patients 
N = 675 
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(81%) during the procedure. Nearly 30% of patients received glycoprotein IIb/IIIa inhibitors and 
heparin based products all of which were not significantly different between both groups (Table 
2). However, the majority of patients on anticoagulation received clopidogrel (74% vs 46%, 
p=0.016) and prasugrel was given to a significantly higher proportion of patients who were not 
on anticoagulation (34% vs 10%, p=0.03) (Table 2).  
 
All patients were on warfarin in the OAC group. The laboratory measurement of pre-procedural 
INR was available in 19 (95%) patients who were on OAC. The mean and median IINRs were 
2.1 and 2.0 respectively and the range was from 1.2 to 4.7. The INR was subtherapeutic (<2.0) in 
9 (47%) Similarly, in the non OAC group, INR data was available in 362 (59%) of patients. The 
mean and median INR were 1.2 ± 0.3 and 1.1 respectively. The range was from 0.9 to 4.2 and 6 
(1.7%) patients had an INR more than 2 from other comorbid conditions such liver disease. 
 
The choice of revascularization methods was different between both groups. Patients who were 
on anticoagulation received more bare metal stents (75% vs. 33%) and none of them underwent 
CABG surgery. Nearly 60% of patients received drug eluting stents when not on anticoagulation 
at admission (p<0.001). Post procedural data shows that the hemoglobin difference remained 
significant between both groups (non OAC group: 12.1 ± 2.1 vs. OAC group: 10.8 ± 2.1, 
p<0.001). However, the change in hemoglobin levels was similar among both groups of patients. 
The OAC group has a drop of 2.2 ± 1.5 gm/dL in hemoglobin (from 14.3 ± 2.1 gm/dL to 12.1 ± 
2.1 gm/dL) and OAC group had a drop of 1.8 ± 1 gm/dL in hemoglobin (from 12.5 ± 2.3 gm/dL 
to 10.8 ± 2.1 gm/dL) (p = 0.13). Post procedural creatinine was significantly higher in patients 
who were on anticoagulation.  
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Table 1: Baseline demographics, medical conditions, and home medications of the study population 
Variable Group 1 
(Not on OAC) 
(N=617) 
Group 2 
(On OAC) 
(N=20) 
Total 
 (N=637) 
P-
Value 
Demographics 
Age (years) 60.9 ± 13.1 67.1 ± 13.2  61.1 ± 13.1 0.039¹ 
BMI (kg/m
2
) 28.8 ± 5.9 (N=611) 30.9 ± 8.8  28.9 ± 6.0  0.51¹ 
Gender     
    Female 175 (28.4%) 9 (45.0%) 184 (28.9%) 0.11¹ 
    Male 442 (71.6%) 11 (55.0%) 453 (71.1%)  
Race     
    Caucasian 508 (82.5%) 16 (80.0%) 524 (82.4%) 0.88¹ 
    African American 73 (11.9%) 4 (20.0%) 77 (12.1%)  
     
Baseline Risk Factors and Medical Conditions 
Hypertension 395 (64.0%) 18 (90.0%) 413 (64.8%) 0.017² 
Diabetes Mellitus 132 (21.4%) 8 (40.0%) 140 (22.0%) 0.048² 
Dyslipidemia 382 (61.9%) 19 (95.0%) 401 (63.0%) 0.0026
² 
Smoking History 255 (41.3%) 6 (30.0%) 261 (41.0%) 0.31² 
COPD 43 (7.0%) 3 (15.0%) 46 (7.2%) 0.17² 
Family History of 
Premature CAD 
22 (3.6%) 7 (35.0%) 29 (4.6%) <.000
1² 
PVD 51 (8.3%) 5 (25.0%) 56 (8.8%) 0.0093
² 
Prior MI 122 (19.8%) 8 (40.0%) 130 (20.4%) 0.027² 
Prior PCI 140 (22.7%) 10 (50.0%) 150 (23.5%) 0.0046
² 
Prior PCI within 1 Yr 33 (23.6%) 3 (30.0%) 36 (24.0%) 0.65² 
Prior CABG 48 (7.8%) 3 (15.0%) 51 (8.0%) 0.24² 
Congestive Heart 
Failure 
32 (5.2%) 5 (25.0%) 37 (5.8%) 0.0002
² 
Currently on Dialysis 9 (1.5%) 1 (5.0%) 10 (1.6%) 0.21² 
Atrial Fibrillation 14 (2.3%) 10 (50.0%) 24 (3.8%) <.000
1² 
Prior History of 
DVT/PE 
6 (1.0%) 6 (30.0%) 12 (1.9%) <.000
1² 
Dilated 
Cardiomyopathy 
0 (0.0%) 1 (5.0%) 1 (0.2%) <.000
1² 
Anemia 17 (2.8%) 2 (10.0%) 19 (3.0%) 0.061² 
Hypothyroid 28 (4.5%) 2 (10.0%) 30 (4.7%) 0.26² 
Obstructive Sleep 
Apnea 
20 (3.2%) 1 (5.0%) 21 (3.3%) 0.66² 
No of CAD Risk 
Factors 
1.9 ± 1.1 2.9 ± 0.7 2.0 ± 1.1 <.000
1¹ 
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Home Medications Prior Index Admission 
Aspirin 226 (36.6%) 11 (55.0%) 237 (37.2%) 0.094² 
Plavix 85 (13.8%) 3 (15.0%) 88 (13.8%) 0.88² 
ACE Inhibitors/ARB 181 (29.3%) 11 (55.0%) 192 (30.1%) 0.014² 
Beta Blockers 156 (25.3%) 10 (50.0%) 166 (26.1%) 0.013² 
Diuretics 101 (16.4%) 8 (40.0%) 109 (17.1%) 0.0058
² 
Calcium Channel 
Blockers 
81 (13.1%) 2 (10.0%) 83 (13.0%) 0.68² 
Statins 212 (34.4%) 12 (60.0%) 224 (35.2%) 0.018² 
Digoxin 5 (0.8%) 2 (10.0%) 7 (1.1%) 0.0001
² 
Vasodilators 24 (3.9%) 1 (5.0%) 25 (3.9%) 0.80² 
Antiarrhythmics 6 (1.0%) 2 (10.0%) 8 (1.3%) 0.0004
² 
Proton Pump Inhibitors 91 (14.7%) 3 (15.0%) 94 (14.8%) 0.98² 
Thyroid Replacement 39 (6.3%) 2 (10.0%) 41 (6.4%) 0.51² 
Insulin 42 (6.8%) 5 (25.0%) 47 (7.4%) 0.0022
² 
Oral Hypoglycemics 73 (11.8%) 4 (20.0%) 77 (12.1%) 0.27² 
¹ based on Mann-Whitney U test; ² based on Fisher's exact test. ACE: Angiotensin converting enzyme, 
ARB: Angiotensin receptor blocker, BMI: Body mass index, CAD: Coronary artery disease, DVT: Deep 
vein thrombosis, COPD: Chronic obstructive pulmonary disease, OAC: Oral anticoagulation, PE: 
Pulmonary embolism, PVD: Peripheral vascular disease.  
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Table 2: Cardiac catheterization procedural details by Anticoagulation status. 
Variable Group 1 
(Not on OAC) 
(N=617) 
Group 2 
(On OAC) 
(N=20) 
Total 
 (N=637) 
P-Value 
Pre Procedural Data 
LVEF (%) 45.5 ± 12.3  40.4 ± 12.3 45.4 ± 12.3  0.11¹ 
ECG Diagnosis based on     
    First ECG 365 (70.7%) 13 (81.3%) 378 (71.1%) 0.58³ 
    Subsequent ECG 151 (29.3%) 3 (18.8%) 154 (28.9%) 
Hemoglobin (gm/dL) 14.3 ± 2.1  12.5 ± 2.3  14.2 ± 2.1  0.001¹ 
Creatinine (mg/dL)  1.1 ± 1.0  1.1 ± 0.4 1.1 ± 1.0  0.44¹ 
Troponin T (ng/ml)  0.6 ± 1.7  0.3 ± 0.4  0.5 ± 1.7  0.85¹ 
INR  1.2 ± 0.3  2.1 ± 1.0  1.2 ± 0.4  <.0001¹ 
Procedural Data 
Contrast Volume (ml) 214.5 ± 98.6  192.3 ± 57.2 213.8 ± 97.6 0.36¹ 
Fluoroscopy Time (min) 14.8 ± 9.2 13.4 ± 9.3 14.7 ± 9.2 0.28¹ 
PCI Delay > 90 min 72 (11.7%) 1 (5.0%) 73 (11.5%) 0.72³ 
Transferred from non-PCI 
capable Hospital 
87 (14.5%) 0 (0.0%)  87 (14.1%)
  
0.092³ 
Arterial Access – Femoral  529 (92.6%) 17 (85%) 546 (92.4%) 0.25³ 
Arterial Access – Radial 42 (7.4%) 3 (15%) 45 (7.6%) 
Medications Administered (Immediately Before or During Cardiac Catheterization) 
Aspirin 515 (83.7%) 18 (94.7%) 533 (84.1%) 0.20² 
Clopidogrel 280 (45.7%) 14 (73.7%) 294 (46.5%) 0.016² 
Prasugrel 210 (34.1%) 2 (10.5%) 212 (33.4%) 0.032² 
Bivalirudin 495 (80.4%) 16 (84.2%) 511 (80.5%) 1.00³ 
GP IIb/IIIa Inhibitor 185 (30.0%) 4 (21.1%) 189 (29.8%) 0.40² 
LMWH/ Fondaparinux 14 (2.3%) 2 (10.5%) 16 (2.5%) 0.079³ 
Unfractionated Heparin 197 (32.0%) 5 (26.3%) 202 (31.8%) 0.60² 
Revascularization Methods Used 
Bare Metal Stent 195 (31.6%) 15 (75.0%) 210 (33.9%) <0.001² 
Drug Eluting Stent 348 (56.4%) 2 (10.0%) 350 (55.4%) 
CABG 24 (3.9%) 0 (0.0%) 24 (3.8%) 
PTCA Only 50 (8.1%) 3 (15.0%) 53 (10.4%) 
Laboratory Findings 
Post Procedural 
Hemoglobin (gm/dL) 
12.1 ± 2.1 10.8 ± 2.1 12.1 ± 2.1 0.0067¹ 
Post Procedural Creatinine 
(mg/dL)  
1.2 ± 1.2  1.4 ± 0.8  1.2 ± 1.2  0.025¹ 
Hemoglobin Change 
(gm/dL) 
-2.2 ± 1.5 -1.8 ± 1.0  -2.2 ± 1.5 0.13¹ 
Creatinine Change 0.1 ± 0.5  0.3 ± 0.7  0.1 ± 0.5  0.097¹ 
Bleeding Complications 
Bleeding in 72 hrs/ Blood 27 (4.4%) 0 (0.0%) 27 (4.2%) 0.41² 
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Transfusion 
Other Complications 
Cardiogenic Shock within 
24 Hrs 
18 (2.9%) 1 (5.0%) 19 (2.8%) 0.44² 
Cardiac Arrest within 24 
Hrs 
32 (5.2%) 0 (0.0%) 32 (5.0%) 0.31² 
Intra-aortic Balloon pump 61 (9.9%) 3 (15.0%) 64 (10.0%) 0.45² 
Mortality and Overall Outcomes 
Length of Stay (days) 3.0 ± 4.6  4.1 ± 5.3  3.0 ± 4.7  0.24¹ 
Hospital Death 38 (6.2%) 2 (10.0%) 40 (6.3%) 0.36³ 
Mortality at 30 day 41 (6.6%) 2 (10.0%) 43 (6.8%) 0.64³ 
Bleeding/Blood 
Transfusion/In-Hospital 
Mortality/Cardiogenic 
Shock/Cardiac arrest 
89 (14.4%) 3 (15%) 92 (14.6%) 1.00³ 
¹ based on Mann-Whitney U test; ² based on Chi-square test; ³ based on Fisher's exact test 
Overall 27 (4.2%) patients developed bleeding complications or required blood transfusion  
 
during the hospital stay. No one in anticoagulation group developed the complication however, 
the difference was not statistically significant (p=0.41). About 10% of overall patients needed 
IABP (intraaortic balloon pump) placement and there was no significant difference between both 
groups (p=0.45). Average length of stay was 3.0 ± 4.7 days which did not differ between both 
groups (p=0.24). Total number of hospital deaths were 40 (6.3%), 38 (6.2%) died in group 1 and 
2 (10%) in group 2 (p=0.36). On composite end point developing bleeding complication, or 
requiring blood transfusion or in-hospital death or developing cardiogenic shock or arrest was 
similar between both groups (14.4% vs 15%, p =1.0). 
 
Predictors of composite end point 
A total of 92 (14.6%) patients developed the composite endpoint. The unadjusted/univariate and 
multivariable analyses are shown in table 3. In multivariable model, pre-procedural hemoglobin 
(OR: 0.88, 95%CI: 0.77-0.98, p=0.012) and requirement of IABP (OR: 4.13, 95% CI: 2.25-7.59, 
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p<0.001) were found to be significant independent predictors. Hosmer-Lemishow goodness-of-
fit statistics for the model was 0.67. For every 1 gm/dL increase at baseline hemoglobin level, 
the odds of developing bleeding complications was reduced by a factor of 0.88. The use of IABP 
increases the odds of developing composite endpoint by 4.13 times when other factors remain 
same. Anticoagulation use and baseline INR were not independent factors for bleeding (Table 3). 
 
 
Table 3: Predictors of composite end point 
Outcome: Composite End Point 
Variable Univariate analysis Multivariable analysis 
 OR 95% CI P value OR 95% CI P value H-L* 
Pre procedural 
Hemoglobin 0.86 0.75 - 0.97 0.02 0.88 0.77 - 0.98 0.012 
 
0.67 
IABP 4.09 2.13 - 7.86 <.001 4.13 2.25 - 7.59 <.001 
Anticoagulation 0.62 0.16 - 3.07 0.56     
INR 1.33 0.61-2.89 0.472     
Age 1.02 0.996 - 1.04 0.11     
Gender  
(Female vs. Male) 0.75 0.43 - 1.32 0.32     
No of CAD Risk 
Factors 1.18 0.94 - 1.47 0.15     
Bivalirudin 0.83 0.39 - 1.78 0.63     
Glycoprotein 
IIb/IIIa inhibitor  1.22 0.68 - 2.19 0.50     
*Hosmer-Lemishow goodness of fit statistic. CAD: Coronary artery disease, CI: Confidence 
interval, IABP: Intraaortic balloon pump, INR: international normalized ratio OR: Odds ratio. 
 
Predictors of bleeding 
Overall, 27 (4.2%) patients developed bleeding complication. Univariate and multivariable 
analyses results were shown in table 4. Revascularization methods, pre procedural hemoglobin 
(OR: 0.61, 95%CI: 0.5-0.73, p<0.001) and IABP (OR: 5.53, 95%CI: 2.13-14.1, p<0.001) use 
were strongly associated with increased risk for bleeding, but not anticoagulation use or INR 
levels or anticoagulation drug of choice (Table 4). Both CABG and DES use were associated 
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with increased bleeding risk or PRBC transfusion. Due to the significant number of patients who 
were subtherapeutic in OAC group, INR was used as a continuous variable in the model in place 
of dichotomous OAC variable to identify any bleeding risk associated with increase in INR. No 
patient in OAC group had bleeding complication and therefore, univariate analysis on OAC 
status was not performed. A total of 24 (3.9%) patients in non OAC group had CABG and all of 
them required blood transfusion. Non-CABG related blood transfusions were only 3 (0.5%) in 
non OAC group and 0 (0%) in OAC group. CABG seems to be the major cause of blood 
transfusion accounting for 24 out of 27 (89%) of PRBC blood transfusion. 
 
 
Table 4: Predictors of bleeding complications 
Outcome: Bleeding/PRBC Transfusion 
Variable Univariate analysis Multivariable analysis 
  OR 95% CI P value OR 95% CI P value H-L* 
Revascularization 
  CABG vs BMS 7.13 1.53-33.32 0.01 7.11 1.62 -31.2 0.017 
 
0.844 
  DES vs BMS 1.22 0.43-3.46 0.71 1.34 0.49 - 3.70 0.10 
  PTCA Only vs BMS 0.46 0.08-2.48 0.37 0.68 0.14 - 3.26 0.568 
Pre-procedural 
Hemoglobin 0.60 0.48-0.75 <0.001 0.61 0.50 - 0.73 <0.001 
IABP  
4.92 1.77-13.71 0.002 5.53 
2.13 -
14.40 <0.001 
INR 1.77 0.50-6.18 0.37     
No of CAD Risk 
Factors 1.08 0.71-1.63 0.72 
    Bivalirudin 1.55 0.39-6.11 0.56 
    Glycoprotein IIb/IIIa 
Inhibitor 0.63 0.22-1.85 0.41 
    Age 1.01 0.97 - 1.04 0.75 
    Gender (Male) 0.57 0.22-1.46 0.24 
    *Hosmer-Lemishow goodness of fit statistic. BMS: Bare metal stent, CABG: Coronary artery 
bypass grafting surgery, CAD: Coronary artery disease, CI: Confidence interval, DES: Drug 
eluting stent, IABP: Intraaortic balloon pump, INR: international normalized ratio, PTCA: 
Percutaneous transluminal coronary angioplasty, OR: Odds ratio. 
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Predictors of in-hospital mortality 
Over all there were (%) deaths in the hospital after admitted with STEMI and underwent primary 
PCI. The univariate variables were shown in table 5. Male gender and less number of CAD risk 
factors at baseline seems to be associated with increased risk of mortality but did not achieve 
statistical significance. On multivariable analysis, Glycoprotein IIb/IIIa use was significant 
factor, however, the model failed Hosmer-Lemishow goodness of fit test. Therefore, no further 
analysis was performed. 
 
Table 5: Predictors of in-hospital mortality. 
Outcome: In-Hospital Mortality 
Variable Unadjusted Analysis 
  Odds Ratio 95% CI P value 
Age 0.98 0.96 - 1.01 0.27 
Gender (Female vs. Male) 0.47 0.21 - 1.07 0.07 
Revascularization 
     CABG vs. BMS 
1.14 0.12 - 10.50 0.91 
     DES vs. BMS 1.86 0.80 - 4.32 0.15 
     PTCA Only vs. BMS 1.21 0.29 - 5.01 0.79 
Anticoagulation 2.67 0.48 - 15.04 0.26 
Pre procedural hemoglobin 0.93 0.77 - 1.12 0.44 
Pre procedural creatinine 0.90 0.46 - 1.76 0.75 
No of CAD Risk Factors 0.74 0.53 - 1.02 0.06 
Bivalirudin 2.11 0.74 - 5.98 0.17 
Glycoprotein IIb/IIIa Inhibitor 0.62 0.28 - 1.39 0.25 
Heparin 1.92 0.71 - 5.18 0.20 
IABP 1.72 0.57 - 5.21 0.34 
BMS: Bare metal stent, CABG: Coronary artery bypass grafting surgery, CAD: Coronary artery 
disease, CI: Confidence interval, DES: Drug eluting stent, IABP: Intraaortic balloon pump, 
PTCA: Percutaneous transluminal coronary angioplasty. 
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Discussion 
Our study showed a prevalence of long-term anticoagulation use of 3.2% in patients with 
STEMI. Similar portions of OAC or anticoagulation use was noted in the other studies of 
patients undergoing PCI [29]. Patients who were on long-term anticoagulation are typically older 
patients and suffer from multiple comorbid conditions. The data is comparable to the previously 
reported data [15, 18, 19, 25].  
 
Our study also showed that patients on OAC are less likely to receive drug eluting stents. The 
results may be explained by conscious decision by the operating interventional cardiologist to 
avoid long-term triple anticoagulation therapy which is associated with increasingly worse long 
term outcomes including bleeding and mortality [37-43]. Similarly, patients on OAC group are 
less likely to receive newer antiplatelet agents such as prasugrel where no evidence existed to 
support their use in combination with warfarin. Although there is significant difference of 
periprocedural and post procedural difference in hemoglobin levels, both groups of patients had 
similar drop in hemoglobin levels and PRBC transfusions. Patients who were on anticoagulation 
had no episodes of major bleeding or required blood transfusion or underwent surgical 
revascularization with CABG. 
 
Predictors of End Points 
Contrary to our expectation, anticoagulation use was not associated with increased risk of 
combined outcomes. Pre procedural hemoglobin and IABP requirements are independent 
predictors of the combined outcomes. In our study group, the majority of patients received 
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bivalirudin. In previous studies which had reported significant increases in bleeding in patients 
received thrombolytics, heparin or glycoprotein IIb/IIIa inhibitors which may explain some of 
the differences. However, this postulated beneficial effect of bivalirudin needs to be established 
in a larger study. The choice of revascularization was also significantly different in both groups. 
Use of bare metal stents may be associated with less aggressive antiplatelet therapy and might 
have contributed to lesser events of bleeding. One possible reason for excess use of bare metal 
stents in patients who were on anticoagulation was to avoid long term dual antiplatelet therapy 
with warfarin which has shown to increase long term bleeding risk. 
 
Predictors of Bleeding 
Interestingly, patients on OAC had no in-hospital bleeding in the study population which was 
different from previously published data. Studies from a large national level ACTION 
Registry®-GWTG™ database, the rate of major bleeding after PCI for STEMI and NSTEMI 
was 11% and home warfarin use was associated with increasing mortality (OR:1.18 and 95% 
CI:1.07–1.30) [33]. However, more recent data from NCDR CathPCI registry based study 
showed the average risk bleeding is 5.8% from more than 1 million procedures done nationwide 
[25]. In our study, over all bleeding risk was only 4.2%. 
 
The paradoxical result may be explained by various reasons. Firstly, physicians are well aware pf 
the risk of bleeding in patients who are on OAC and probably have taken extra precautions to 
achieve low bleeding such as careful access site management which were not studied. Secondly, 
the study cohort has overall less bleeding complications compared to other published studies. For 
example, overall bleeding risk in STEMI patients was reported as high as 11.5% compared to 
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4.2% in our study [44]. There is considerable use of bivalirudin in our cohort compared to 
registry based published data of 40.8% compared to 80.5% in our cohort [44]. Bivalirudin use 
has shown to reduce bleeding risk from 8.3% to 4.9% when compared to Glycoprotein IIb/IIIa 
inhibitor use [45]. However, the effect of bivalirudin use in patients who were on OAC was not 
reported before. Bivalirudin use was not a significant factor in reducing the bleeding on 
multivariable analysis probably due to small sample size. 
 
Similar to combined end point, the major predictors of bleeding were IABP and lower 
hemoglobin levels before primary PCI and CABG surgery. Every patient who went for CABG 
received PRBC infusion which may be expected. Previous studies have shown as high as 27% 
bleeding risk in patients who had IABP for emergent PCI [46]. Recent updated results from 
NCDR data shows that pre-procedural hemoglobin is also a risk factor for bleeding after any 
type of PCI [27]. Our results also support similar findings published in the literature.  
 
Another concern about adherence to INR was identified in the study. Every patient in the group 
of cohort was on warfarin. The advantage with warfarin compared to other anticoagulants was 
that the adherence can be easily identified by simple blood test (INR). In the cohort, 47% 
patients were subtherapeutic defined as INR of less than 2. Previous studies have indicated that 
subtherapeutic INR in patients who were on anticoagulation were as high as 60% [47-49]. The 
subtherapeutic INR might have resulted in a bias towards null resulting in OAC use not a 
significant risk factor for bleeding. 
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Predictors of Mortality 
In-hospital and 30 day mortality in patients with acute STEMI has been reported around 10% 
over last years and is slowly improving [50-53]. Most contemporary data from NCDR showed 
the risk-adjusted in-hospital mortality between 2009 and 2011 for STEMI patients who 
underwent primary PCI was about 5.3% [25], which is similar to our study population. Although 
there is increased mortality in patients who were on OAC, the statistical significance was not 
reached due to small sample size and lack of a statistical model. To our knowledge, there were 
no other direct studies assessing the impact of OAC on mortality in acute STEMI patients.  
 
Generalizability 
The study was conducted in a large community academic center reflecting contemporary 
management patterns in primary PCI. The study shows that there is higher use of bivalirudin, 
prasugrel use compared to other published literature reflecting contemporary changes in the use 
of antiplatelet and antithrombotic use. The study also did not exclude patients who died within 
24 hours or include those patients who were presenting with a different reperfusion strategy other 
than primary PCI. The proportion of patients using anticoagulation is similar to most of other 
published studies. Therefore, the results may be generalizable to all patients who are undergoing 
primary PCI for STEMI under current guidelines. 
 
Limitations:  
Like other retrospective observational studies, there is the potential for unmeasured confounding 
and selection bias, some STEMI patients might have died before reaching hospital. Relatively 
small number of patients in the anticoagulation group limits the power the study and no long 
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term prognostic outcomes were studied. However, the current study provides preliminary data 
for further exploration of hypotheses using data from large national level registry based 
databases. Long term outcomes and recurrent hospitalizations and major cardiac events were not 
studied. A significant number of patients who were on anticoagulation, had sub therapeutic INR 
on presentation which may underestimate the risk of complications in OAC group. 
  
Conclusions 
Overall, 3% of STEMI patients were on long-term anticoagulation at the time of presentation. 
Despite increase in age, and number of comorbid conditions in patients who were on 
anticoagulation, the risks of bleeding and in-hospital mortality were similar to those who were 
not on anticoagulation at the time of STEMI presentation. Patients who were on long term 
anticoagulation were more likely to receive bare metal stents and clopidogrel. The adjusted risk 
of bleeding was significantly higher in patients who had lower hemoglobin at presentation and 
required IABP support or underwent revascularization with CABG. Glycoprotein IIb/IIIa use 
was associated with increased in-hospital mortality. However, due to small number of patients 
who were on OAC, the results needs to be confirmed in a large study.  
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Appendix 1: 
Definitions 
Majority of the definitions used are based on NCDR based CathPCI registry standards (Available 
at www.ncdr.com).  
 
1. STEMI: The patient presented with a ST elevation myocardial infarction (STEMI) or its 
equivalent as documented in the medical record. STEMIs are characterized by the 
presence of both criteria:  
 
a. a. ECG evidence of STEMI: New or presumed new ST-segment elevation or new 
left bundle branch block not documented to be resolved within 20 minutes. ST-
segment elevation is defined by new or presumed new sustained ST-segment 
elevation at the J-point in two contiguous electrocardiogram (ECG) leads with the 
cut-off points: >=0.2 mV in men or >= 0.15mV in women in leads V2-V3 and/or 
>= 0.1 mV in other leads and lasting greater than or equal to 20 minutes. If no 
exact ST-elevation measurement is recorded in the medical chart, physician's 
written documentation of ST-elevation or Q-waves is acceptable. If only one ECG 
is performed, then the assumption that the ST elevation persisted at least the 
required 20 minutes is acceptable. Left bundle branch block (LBBB) refers to new 
or presumed new LBBB on the initial ECG. ST elevation in the posterior chest 
leads (V7 through V9), or ST depression that is maximal in V1-3, without ST-
segment elevation in other leads, demonstrating posterobasal myocardial 
infarction, is considered a STEMI equivalent.  
b. Cardiac biomarkers (creatinine kinase-myocardial band, Troponin T or I) exceed 
the upper limit of normal according to the individual hospital's laboratory 
parameters a clinical presentation which is consistent or suggestive of ischemia.  
 
Note: If laboratory data was pending at the time of cardiac catheterization or 
found out to be normal subsequently but coronary angiogram showing an acute 
thrombus, patient was included in the study as STEMI patient.  
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2. Major Bleeding Complication: Defined as the patient experienced a suspected or 
confirmed bleeding event observed and documented in the medical record that was 
associated with any of the following between start of procedure and 72 hours after 
procedure:  
a. Hemoglobin drop of >=3 g/dL;  
b. Transfusion of whole blood or packed red blood cells;  
c. Procedural intervention/surgery at the bleeding site to reverse/stop or correct the 
bleeding (such as surgical closures/exploration of the arteriotomy site, balloon 
angioplasty to seal an arterial tear, endoscopy with cautery of a GI bleed. 
 
3. Anticoagulation use: Defined as chronic use of systemic anticoagulation agents for at 
least 4 weeks before index hospital admission. The agents that were included in the study 
are warfarin or dabigatran in oral form and low-molecular weight heparin in 
subcutaneous form. If a patient is on warfarin and initial INR is less than 1.5, he is not 
considered on full anticoagulation and treated with other group. If a patient is receiving 
therapeutic dose of low molecular heparin or dabigatran, then the patient is considered to 
be on full anticoagulation irrespective of INR. Of note, newer oral antithrombotic agents 
such as apixaban and rivaroxaban were not included as their use was not approved by 
FDA during the study period.  
 
4. In Hospital Mortality: Obtained from the discharge status of the patient from the 
registry where it was mentioned as patient died in the hospital. It was confirmed by 
manual review of medical chart and verifying a copy of death certificate. 
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Appendix 2 
 
Elements of Data Collection 
 
The following data point were collected by electronic database query of electronic medical 
records, cardiac catheterization lab database and from the ODS system.  
 
1. Demographics 
a. Age, gender, race and BMI 
 
2. Past medical history (presence of ) of the following conditions: 
Hypertension   
Diabetes  
Hyperlipidemia 
Current smoking  
Family History of premature CAD 
COPD  
TIA/Stroke  
Peripheral vascular disease 
Previous Diagnosis of CAD 
Previous MI  
Previous PCI   
Previous CABG  
Congestive heart failure  
Chronic kidney disease  
Pre Procedural left ventricular 
ejection fraction  
Anemia  
Atrial fibrillation  
Mechanical heart valve  
Previous cardiac embolism  
Previous venous thromboembolism  
Dilated cardiomyopathy  
Obstructive sleep apnea 
Malignancy 
Previous chemotherapy and radiation 
therapy 
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3. Home medication use at the time of presentation (By classes) 
 
4. Laboratory data 
a. Pre procedure: hemoglobin, INR, creatinine, troponins 
b. Post procedure labs: hemoglobin (lowest in 72 hours) and creatinine (highest) 
 
5. Cardiac cath lab data 
a. Procedural medications used 
Aspirin  
Bivalirudin  
GP IIb/IIIa Inhibitors 
Low Molecular Weight Heparin/ Fondaparinux 
Unfractionated Heparin 
Clopidogrel 
 
b. Hemodynamic support 
a. IABP 
c. Revascularization 
a. Primary PCI (type of stents drug eluting or bare metal) 
b. CABG (Status and Indication) 
c. PTCA only 
 
6. In-hospital outcomes 
a. Length of stay 
b. Complications including major bleed, minor bleed, stroke 
c. Cardiogenic shock 
d. In-hospital mortality 
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